Last reviewed · How we verify
NYHA Class III-IV heart failure with reduced ejection fraction
Approved treatments
- Aldactone · Pfizer Inc.
Aldosterone antagonist causing increased sodium and water excretion while retaining potassium.
Clinical guidelines
- FDA label — adjuvant
Spironolactone is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone is usually administered in conjunction with other heart failure therapies.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- NYHA Class III-IV heart failure with reduced ejection fraction patent landscape — cliff calendar, originator estates, attackable patents
- NYHA Class III-IV heart failure with reduced ejection fraction treatment landscape brief
- NYHA Class III-IV heart failure with reduced ejection fraction treatment updates RSS
Frequently asked questions about NYHA Class III-IV heart failure with reduced ejection fraction
What drugs treat NYHA Class III-IV heart failure with reduced ejection fraction?
Tracked treatments include Aldactone.
What is the treatment for NYHA Class III-IV heart failure with reduced ejection fraction?
Standard treatment for NYHA Class III-IV heart failure with reduced ejection fraction includes Aldactone. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for NYHA Class III-IV heart failure with reduced ejection fraction?
FDA label publishes guidelines for NYHA Class III-IV heart failure with reduced ejection fraction. 1 guideline references tracked.
Related
- Treatment landscape: NYHA Class III-IV heart failure with reduced ejection fraction patent cliff · NYHA Class III-IV heart failure with reduced ejection fraction CI report
- Treatment: Aldactone · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing